Key Points
- Braveheart Bio director David Charles Lubner purchased 55,555 shares at an average price of $18.00, for a total investment of approximately $1 million.
- Following the transaction, Lubner directly owned 55,555 shares of the company; the purchase was disclosed in a filing with the Securities and Exchange Commission.
- BRVE shares opened at $30.00 and were up 0.7%, trading within a 12-month range of $28.47 to $32.00. Braveheart Bio is developing BHB-1893, an oral cardiac myosin inhibitor for hypertrophic cardiomyopathy.
Braveheart Bio, Inc. (NASDAQ:BRVE - Get Free Report) insider Michele Anderson acquired 1,111 shares of Braveheart Bio stock in a transaction that occurred on Friday, August 7th. The shares were purchased at an average cost of $18.00 per share, with a total value of $19,998.00. Following the completion of the acquisition, the insider owned 332,161 shares of the company's stock, valued at $5,978,898. The trade was a 0.34% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Braveheart Bio Trading Up 0.7%
Braveheart Bio stock opened at $30.00 on Friday. Braveheart Bio, Inc. has a fifty-two week low of $28.47 and a fifty-two week high of $32.00.
Braveheart Bio Company Profile
(
Get Free Report)
We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
